E a vida continua para este casal. Nunca eh tarde demais para fazer o que queremos fazer! Pessoal, vamos aderir a este abaixo assinado pedindo mais pesquisas no Brasil com o estudo de celulas tronco.Os pacientes agradecem!!!!! Proposed PDUFA Agreement: the Right Prescription for People with Lou Gehrig's DiseaseSeptember 6, 2011WASHINGTON, DC (September 6, 2011) The ALS Association applauds the proposed agreement for the reauthorization of the Prescription Drug User Fee Act (PDUFA), which includes provisions that would help to encourage and expedite the approval of new treatments for rare diseases like ALS, also known as Lou Gehrigs Disease. The proposed agreement was released by the Food and Drug Administration (FDA) on September 1. PDUFA authorizes the FDA to collect fees from companies that develop drugs and biologic products. These fees help the agency cover the costs of drug reviews and currently account for about half of the agencys drug review costs. The law originally was established in 1992 and has been reauthorized every five years since that time. The current law expires next year unless it is reauthorized by September 30, 2012. The reauthorization of PDUFA is critical to discovering a treatment and cure for ALS, said Jane Gilbert, President and CEO of The ALS Association. There is no effective treatment for ALS and it is fatal in an average of just two to five years. By providing the agency with the resources it needs to review new treatments and ensure their efficacy and safety, PDUFA helps to make sure that funding limitations do not block innovative treatments from reaching the patients who so urgently need them. The additional resources and the establishment of drug review timeframes are important elements of PDUFA, said Steve Gibson, The ALS Associations Chief Public Policy Officer. This proposal is particularly significant because it was developed with the input of the patient community in partnership with the FDA and industry. And it is significant because it includes key provisions that promote the development of new treatments and recognize that the practice of medicine is not a one-size-fits-all proposition, especially when it comes to a disease like Lou Gehrigs Disease. Since July 2010, The ALS Association participated in monthly meetings with FDA officials to bring the perspective of people with ALS to the discussion on the reauthorization of PDUFA. Three key provisions advocated by The Association were included in the proposed agreement. They include: Developing Treatments for Rare Diseases: Directs FDA to issue regulatory policies and guidance that encourage the development of drugs to treat rare diseases and to include patients as active participants in this process. Assessing Risk-Benefit: Instructs the agency to develop an objective and qualitative framework for assessing risk and benefit during the drug review process and to ensure patient involvement. The provision takes into account the fact that people with ALS who have no treatment options and who will die in just two to five years have a much different view of risk and benefit than does someone with a treatable or chronic condition. Utilizing Biomarkers in Clinical Trials: The proposal encourages greater